Cohera Medical, Inc.® President and CEO, Patrick Daly, Appointed to AdvaMed Board of Directors

Apr 15, 2014, 08:00 ET from Cohera Medical, Inc.


PITTSBURGH, April 15, 2014 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that the Company's President and Chief Executive Officer, Patrick Daly, has been appointed to the Advanced Medical Technology Association's (AdvaMed) Board of Directors.

AdvaMed is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. It represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems.

"AdvaMed is excited to have Patrick join the association's Board of Directors," said Steve Ubl, AdvaMed President and CEO. "He has a wealth of experience in the medical device space, particularly in international issues which is one of AdvaMed's strategic priority areas. But most importantly, he understands the needs of smaller and emerging growth companies – from venture financing to regulatory approval to access in overseas markets – and his insights will be key as we focus even further on the issues impacting this important segment of our industry."

Mr. Daly started Cohera Medical in 2006 and serves as its President and Chief Executive Officer. Under Mr. Daly's leadership, Cohera Medical has raised $75M in private funding to support the development, clinical research, and regulatory applications for its TissuGlu® Surgical Adhesive and Sylys® Surgical Sealant. Cohera Medical announced in December 2013 that it had submitted its fourth and final module for TissuGlu in a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA).

About the Advanced Medical Technology Association (AdvaMed)

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit

About Cohera Medical

Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that help eliminate or reduce fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for marketing by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.

SOURCE Cohera Medical, Inc.